Sanofi Demonstrates Commitment to Innovative Diabetes Care at International Diabetes Technology Conference

 Sanofi Demonstrates Commitment to Innovative Diabetes Care at International
                        Diabetes Technology Conference

  PR Newswire

  PARIS, February 25, 2013

PARIS, February 25, 2013 /PRNewswire/ --

  - Data presented at ATTD by Sanofi will focus on the company's integrated
portfolio of therapeutic solutions, blood glucose monitoring, insulin delivery
              and contributions to advancing diabetes research -

Sanofi (EURONEXT: SANand NYSE: SNY) announced today that its comprehensive
portfolio of innovative diabetes solutions will be presented at the
International Conference on Advanced Technologies & Treatments for Diabetes
(ATTD) in Paris, France (February 27 - March 2). The annual ATTD conference is
the leading diabetes technology meeting in Europe, and Sanofi will showcase
its commitment to advancing therapeutic solutions and diabetes care technology
aimed at improving patient outcomes.

Abstracts include the latest clinical data on the early benefits of Lantus ^®
(insulin glargine), the accuracy, reliability and ease-of-use of the BGStar ^®
and iBGStar ^® blood glucose meters, and the SoloSTAR ^® insulin delivery
device. The study design of the biggest multi-national register of diabetes
research in the young, TEENS, will also be featured.

In addition, Sanofi will sponsor a plenary satellite symposium at ATTD titled
" Technology: Contributing to Diabetes Management Today and Tomorrow " which
will provide an overview of current and future treatments, tools and projects
to facilitate clinical decision making and empower patients to take control of
their diabetes. The session will conclude with a presentation on the
artificial pancreas in children.

" Today, effective diabetes management is increasingly a matter of simplifying
day-to-day routines for people living with the condi tion. This means we need
 c omprehensive  approaches to diabetes care based on technological
advances, " said Pierre Chancel, Senior Vice President, Sanofi, Global
Diabetes. " Sanofi ' s diabetes teams are dedicated to providing innovative
and integrated technological solutions combined with patient support services
that help people with diabetes effectively manage their disease while living
the lives they want to live. "

Highlights of the data being presented are as follows (abstracts are available
on the ATTD website http://www2.kenes.com/attd ):

iNewTrend study:  " Effect of Glucose Monitoring with Smartphone Integration
on Metabolic Control and Compliance in Type 1 Diabetes (iNew Trend): Study
Design "

When:Session 26: Oral Presentations, Saturday 2 March, 12:20 - 12:30pm
CET Presenter: V. Cherubini, Polytechnic University of Marche, Ancona, Italy
Where:CNIT Paris La Defense Exhibition Hall, Hall III

EARLY LANTUS study:  " Early Onset of Glycaemic Improvements after Insulin
Initiation with Insulin Glargine in Patients with Type 2 Diabetes Mellitus
Uncontrolled with OADs: Pooled Analysis from Clinical Trials "

When: Poster Session 2, Friday 1 March, 8:00am - 17:00pm CET
Presenter: D.R. Owens, Institute of Molecular and Experimental Medicine,
Cardiff, UK Where: CNIT Paris La Defense Exhibition Hall, Poster Area

LANTUS  survey :  " Survey on Physician Experiences in Initiation of Insulin
in Type 2 Diabetes Patients: Preliminary Results for Insulin Glargine "

When:Poster Session 2, Friday 1 March, 8:00am - 17:00pm CET
Presenter: R. Roussel, Diabetology, Endocrinology and Nutrition Department,
Paris, France Where:CNIT Paris La Defense Exhibition Hall, Poster Area

TEENS study:  " International Evaluation of Diabetes Management, Glycaemic
Control and Quality of Life in Youth with Type 1 Diabetes: the TEENS Study "

When: E-Poster Session 4, Friday 1 March, 10:00am CET Presenter: L.
Laffel, Harvard Medical School, Boston, USA Where:CNIT Paris La Defense
Exhibition Hall, Exhibition Area, Poster Station 2

BGStar ^®  and iBGStar ^®  abstracts include:

"Assessment of Ascorbic Acid and Acetaminophen Interference on the Performance
of Blood Glucose Meters for Patient Self-Testing"

When:Poster Session, Thursday 28 February, 8:00am - 17:00pm CET
Presenter: A. Pfützner, IKFE - Institute for Clinical Research and
Development, Mainz, Germany Where:CNIT Paris La Defense Exhibition
Hall, Poster Area

"Laboratory Study for Evaluation of the Influence of Temperature and Humidity
on Blood Glucose Measurements with BGStar and iBGStar"

When:Poster Session, Thursday 28 February, 8:00am - 17:00pm CET
Presenter: A. Pfützner, IKFE - Institute for Clinical Research and
Development, Mainz, Germany Where:CNIT Paris La Defense Exhibition
Hall, Poster Area

"Performance of Current Blood Glucose Meters in Compliance with the New Draft
Clinical ISO15197: 2010 Accuracy Criteria"

When:Poster Session, Thursday 28 February, 8:00am - 17:00pm CET
Presenter: A. Pfützner, IKFE - Institute for Clinical Research and
Development, Mainz, Germany Where:CNIT Paris La Defense Exhibition
Hall, Poster Area

"Impact of Strip Filling on the Performance of Glucose Meters for Patient
Self-Testing"

When:Poster Session, Thursday 28 February, 8:00am - 17:00pm CET
Presenter: A. Pfützner, IKFE - Institute for Clinical Research and
Development, Mainz, Germany Where:CNIT Paris La Defense Exhibition
Hall, Poster Area

SoloSTAR ^®  abstracts include:

" Field Study on Rotational Speeds and Angles used by Patients Dialing a Dose
on Four Different Disposable Insulin Pens"

When:E-Poster Session 1, Thursday 28 February, 10:05am CET
Presenter: A. Friedrichs, LWS Risk Management Consult GmbH, Brannenburg,
Germany Where:CNIT Paris La Defense Exhibition Hall, Exhibition Area,
Poster Station 1

"Torque for Dose Dialing of Four Disposable Insulin Pens SoloSTAR, FlexTouch,
FlexPen, and KwikPen: Results of a Laboratory Study"

When:Poster Session 2, Friday 1 March, 8:00am - 17:00pm CET
Presenter: A. Friedrichs, LWS Risk Management Consult GmbH, Brannenburg,
Germany Where:CNIT Paris La Defense Exhibition Hall, Poster Area

Sanofi-Sponsored Plenary Satellite Symposium:

"Technology: Contributing to Diabetes Management Today and Tomorrow"

When:   Session 8: Plenary Satellite Symposium, Thursday 28 February,
15:00 - 16:30pm CET Chairman:  L. Heinemann, Profil Institute for Metabolic
Research, Neuss, Germany Where:  CNIT Paris La Defense Exhibition Hall,
Hall I

About Diabetes

Diabetes is a chronic disease that occurs as type 1 diabetes, which is an
autoimmune disease characterized by the lack of insulin (the hormone that
regulates blood glucose concentrations) production by the pancreas, and type
2, a metabolic disorder in which there are two main biological defects: a
deficient production of insulin and reduced ability of the body to respond to
the insulin being produced. Type 1 and type 2 diabetes are characterized by an
increase in blood glucose concentrations (hyperglycemia). Over time,
uncontrolled hyperglycemia leads to the macrovascular and microvascular
complications of diabetes. Macrovascular complications, which affect the large
blood vessels, include heart attack, stroke and peripheral vascular disease.
Microvascular complications affect the small blood vessels of the eyes
(retinopathy), kidney (nephropathy) and nerves (neuropathy). The global
incidence of diabetes is growing at an alarming rate, with more than 371
million people worldwide living with the condition today. ^[i]

About Sanofi Diabetes

Sanofi strives to help people manage the complex challenge of diabetes by
delivering innovative, integrated and personalized solutions. Driven by
valuable insights that come from listening to and engaging with people living
with diabetes, the Company is forming partnerships to offer diagnostics,
therapies, services and devices, including intelligent blood glucose
monitoring systems. Sanofi markets both injectable and oral medications for
people with type 1 or type 2 diabetes.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product development
and potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans" and similar expressions. Although
Sanofi's management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally beyond the
control of Sanofi, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA, regarding
whether and when to approve any drug, device or biological application that
may be filed for any such product candidates as well as their decisions
regarding labelling and other matters that could affect the availability or
commercial potential of such product candidates, the absence of guarantee that
the product candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group's
ability to benefit from external growth opportunities, trends in exchange
rates and prevailing interest rates, the impact of cost containment policies
and subsequent changes thereto, the average number of shares outstanding as
well as those discussed or identified in the public filings with the SEC and
the AMF made by Sanofi, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual
report on Form 20-F for the year ended December 31, 2011. Other than as
required by applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.



References

i. International Diabetes Federation.IDF Diabetes Atlas, 5th edn. Brussels,
Belgium: International Diabetes Federation, 2011.
http://www.idf.org/diabetesatlas (Accessed: February 14, 2013 - 17:30 pm)

Contacts:

Global Diabetes Division Diagnostics and Delivery SolutionsMilena Saleh
Mobile: +49-173-68-96-040 E-mail: Milena.Saleh@sanofi.com